Purchase this article with an account.
Nicolas Molina, Raoul A. Saint-Jean, Josep Torras, Merce Morral, Maite Sainz de la Maza; Ocular Side Effects Of Inhibitors Of The Epidermal Growth Factor Receptor: Report Of 4 Cases. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1997.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the ocular effects associated with the administrationof epidermal growth factor (EGF) receptor inhibitors, Panitumumaband Erlotinib.
Noncomparative interventional case series included 8 eyes of4 patients in treatment with EGF receptor inhibitors, 3 withErlotinib for end-stage lung carcinoma and 1 with Panitumumabfor end-stage colorectal cancer.
Multiple epithelial defects were observed in 8 eyes, cornealmelting and thinning were observed in 3 eyes of 2 patients,2 eyes of 1 patient presented with lower lid ectropion, andcorneal perforation in 2 eyes of 2 patients, both requiringa penetrating keratoplasty.
Severe ocular side effects, including perforated corneal ulcers,may be associated with the use of the EGF inhibitors panitumaband erlotinib.
This PDF is available to Subscribers Only